Biohaven has dosed the first subject in its Phase I/II clinical trial of BHV-1510, a trophoblast cell surface antigen-2 (Trop-2) directed antibody-drug conjugate (ADC) for advanced or metastatic epithelial cell tumours.

It is a first-in-human, multi-centre, open-label trial structured into two segments: a Phase I dose escalation and a multicohort Phase II dose expansion.

The initial phase will focus on determining the safety and tolerability of BHV-1510, establishing the recommended doses for expansion (RDEs), and identifying the maximum-tolerated dose (MTD), if applicable.

The subsequent phase will evaluate the preliminary efficacy of the drug in signal-finding expansion cohorts.

BHV-1510 features a homogeneous drug-antibody ratio (DAR) of four and employs a Trop-2-directed antibody linked to a Topoisomerase 1 (TopoIx) payload.

The ADC employs a unique site-specific conjugation method and a highly stable and irreversible linker developed by GeneQuantum Healthcare.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Preclinical studies have demonstrated that BHV-1510 delivers cellular cytotoxicity, bystander killing, and immunogenic cell death, potentially leading to enhanced monotherapy efficacy and synergistic effects along with anti-PD-1 therapy.

BHV-1510 exhibited a wider therapeutic margin compared to other Trop-2 ADCs in IND-enabling studies, notably without lung toxicity. This suggests a possible improvement in the clinical efficacy and safety profile for patients.

Furthermore, Biohaven signed a clinical supply agreement with Regeneron Pharmaceuticals.

Under this agreement, Biohaven will sponsor and fund the clinical trial, while Regeneron will provide Libtayo, a fully human monoclonal antibody targeting the PD-1 immune checkpoint receptor.

Biohaven Oncology chief medical officer Nushmia Khokhar said: “We are extremely proud to advance our first oncology clinical programme with a potentially best-in-class ADC.

“With the initiation of this monotherapy study, we are one step closer to providing differentiated and superior treatment options to people living with cancer. We are also excited to work with Regeneron and efficiently explore BHV-1510 in combination with its PD-1 inhibitor Libtayo across a range of tumours.”

Last September, the company concluded the enrolment of 180 patients in a Phase III study evaluating taldefgrobep alfa as adjunctive therapy in patients with spinal muscular atrophy (SMA).